MedDataX Logo

Clinical Performance and Safety of the VITA AV Clinical System

NCT ID: NCT06207227

Last Updated: 2024-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-13

Study Completion Date

2024-09-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this clinical investigation is to demonstrate that treatment with the VITA AV clinical system is feasible and to evaluate clinical performance and safety when used to improve the symptoms and signs of vaginal atrophy (VA) due to menopause.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After recruitment of the subject, the initial assessment of the enrolled patient will be performed, which includes screening, baseline evaluations \& pre-procedural assessments, suitability of device size for each patient (vaginal dilator kit- for sizing and recording) and endoscopic images will be done by the clinician.

Subjects will be introduced to the therapy over a 2-4week familiarisation period to determine their dosage. Subsequently, subjects will receive 3x treatment sessions over a 12-week window with a final follow-up 4 weeks after the final treatment session.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaginal Atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VITA AV Clinical System

VITA AV Clinical System

Group Type EXPERIMENTAL

VITA AV Clinical System

Intervention Type DEVICE

The VITA AV Clinical System that works on the principle of negative pressure suction to the vaginal wall to treat VA, based on the idea of the clinical application in wound healing which is intended to elicit improvements in the rate of angiogenesis, moisture and HA production post-treatment. It is believed that the VITA AV Clinical System will provide a more effective treatment by improving the underlying cellular deficiencies associated with VA.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VITA AV Clinical System

The VITA AV Clinical System that works on the principle of negative pressure suction to the vaginal wall to treat VA, based on the idea of the clinical application in wound healing which is intended to elicit improvements in the rate of angiogenesis, moisture and HA production post-treatment. It is believed that the VITA AV Clinical System will provide a more effective treatment by improving the underlying cellular deficiencies associated with VA.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy postmenopausal women from 51 years up to and including 70 years.
2. The subject must be able to identify an MBS of at least moderate severity from one of the following: vaginal dryness, itching, discharge, and dyspareunia (pain during intercourse).
3. Vaginal Health Index (VHI) score between 6-15, indicating mild to moderate VA.
4. The one-size intravaginal tip "VITA AV probe Kit" fits comfortably within the subject's vagina. Clinician to size the vagina using the vaginal dilator sizing kit and record the size on the assessment/record sheet. (25mm diameter, 60mm length). Urethral opening is distal to device sealing collar.
5. Normal Papanicolaou test within the past year (or should be done before the trial begins or 2 weeks before F1). Subject can ONLY participate on negative results.
6. Vaginal canal free of any lesions or abnormalities other than signs of VA.
7. Willing and able to sign an Informed Consent Form (ICF).
8. Subjects must be willing to refrain from sexual intercourse for 48 hours before initial assessment, for 48 hours before and after each session \[Familiarisation (F) and Treatment (T)\] and for 48 hours before final follow-up visit.
9. Subjects must be willing to stop using any lubricant at least 48hrs before initial assessment (as if they use lubricant, it will affect sizing)before and after each session \[Familiarisation (F) and Treatment (T)\] and for 48 hours before final follow-up visit. Only use lubricant provided by the clinic to aid sexual intercourse
10. Subjects must be willing to discontinue/stop dilator/pelvic floor therapy 7 days before initial assessment and this therapy should not continue if the patient is participating in trial.

Exclusion Criteria

1. Vaginal Health Index (VHI) score of 5 or less (indicates severe VA).
2. Subjects on Hormone Replacement Therapies (HRT), systemic or local, or within 6 months of cessation of HRT prior to inclusion in the study.
3. Use of vaginal moisturisers, or any other local vaginal preparation within 3 months prior to study inclusion.

Note: The use of simple non-moisturising lubricants to aid sexual intercourse can be accepted in the study.
4. Subjects with bleeding disorders.
5. Subjects on prescribed blood thinners such as antiplatelets and anticoagulants (Heparins, Warfarin or Clopidogrel).
6. Acute UTIs.
7. Any active genital infections.
8. Abnormal Pap smear test.
9. Positive pregnancy test or planned pregnancy during the study period.
10. Uterine prolapse.
11. Subjects with urogenital sinus (this is when urethral opening is combined with the vagina opening), otherwise the urethral opening will be traumatized resulting in an UTI.
12. Undergone pelvic surgery within 6 months prior to the start of the study.
13. Undiagnosed vaginal bleeding.
14. Cancer patients on chemotherapy or subjects with any diagnosed gynaecological cancers.
15. Breast cancer survivors who have had chemotherapy within the last 5 years or are on aromatase inhibitors.
16. Subjects where the one-size VITA AV intravaginal tip does not fit comfortably within the patient's vagina (in the clinician's opinion).
17. Any serious disease or chronic condition that could jeopardize the subject's ability to complete the trial assessments.
18. Subjects who, in the opinion of the investigator, will be inappropriate for inclusion in this study or will not comply with the requirements of the study.
19. Subjects who do not have the mental or physical ability to comply with time schedules and further study procedures.
20. Subjects with urinary symptoms as their MBS will be excluded from the study due to other potential causes of this symptom.
Minimum Eligible Age

51 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AVeta Medical

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pineo Clinic (Pineo Medical Ecosystem)

Tbilisi, , Georgia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Georgia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

10545

Identifier Type: -

Identifier Source: org_study_id